Heron Therapeutics Gets a Buy Rating from Cantor Fitzgerald


Cantor Fitzgerald analyst Louise Chen assigned a Buy rating to Heron Therapeutics (NASDAQ: HRTX) yesterday and set a price target of $50. The company’s shares closed yesterday at $37.75.

Chen observed:

“. We reaffirm our OW rating and are raising our 12-month PT for HRTX shares to $50 from $40 after spending a day on the road with CEO July 18. The increase in our PT is driven by multiple expansion, which is supported by what we think will be a faster-than-expected product launch for HTX-011 next year. Below we highlight the key takeaways from our meetings, which underscore our positive thesis.”

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -4.7% and a 42.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Melinta Therapeutics Inc, Aclaris Therapeutics Inc, and Paratek Pharmaceuticals.

Currently, the analyst consensus on Heron Therapeutics is a Strong Buy with an average price target of $53.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $42.90 and a one-year low of $14.40. Currently, Heron Therapeutics has an average volume of 1.27M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts